<DOC>
	<DOCNO>NCT02167893</DOCNO>
	<brief_summary>The purpose survey design evaluate efficacy safety long-term use ( 96 week ) leuprorelin acetate SR 11.25 milligram ( mg ) injection kit ( Leuplin SR 11.25 mg injection kit ) prostate cancer participant daily medical practice .</brief_summary>
	<brief_title>Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey `` Long-term Use Survey Prostate Cancer Patients ( 96 Weeks ) ''</brief_title>
	<detailed_description>This survey design evaluate efficacy safety long-term use ( 96 week ) leuprorelin acetate 3 month depot injection kit ( Leuplin SR 11.25 mg Injection Kit ) prostate cancer participant daily medical practice . For adult , 11.25 mg leuprorelin acetate usually administer subcutaneously every 12 week . Prior injection , plunger rod syringe push upward needle point upward , allow entire suspension fluid contain transferred powder . The powder fully suspend fluid ensure bubble generate .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Prostate cancer participant meet follow criterion : 1 . Participants prostate cancer initially diagnose January 1 , 2005 2 . Participants prior history treatment Leuplin SR 11.25 mg Injection Kit ( exception , participant prior history treatment Leuplin 3.75 mg Injection Kit may enrol survey ) 3 . Participants prostatespecific antigen ( PSA ) level determine baseline within 3 month prior start treatment Leuplin SR 11.25 mg Injection Kit</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>